Epinephrine Auto-Injector Carry and Use Rates: Carried, Present, Used, Used Right (2026)

How many people with an epinephrine auto-injector actually carry it, have it at the scene, use it during anaphylaxis, and use it correctly? The joined study data — each rate with its population and year, sting-specific figures separated.

Epinephrine Auto-Injector Carry and Use Rates: Carried, Present, Used, Used Right (2026)

Epinephrine Auto-Injector Carry and Use Rates: Carried, Present, Used, Used Right (2026)

41%
In a subset analysis of Canada's national anaphylaxis registry (C-CARE), only 41% of patients who had an epinephrine auto-injector accessible during an anaphylactic reaction used it before reaching hospital.

Source: Gabrielli et al., C-CARE subset analysis, as reported in J Mark Access Health Policy (2026) (2017)

KEY TAKEAWAYS

An epinephrine auto-injector has to survive four separate human decisions before it can work: it has to be carried, it has to be there when the reaction starts, somebody has to decide to use it, and it has to be used correctly. Each of those links has been measured — but never in the same study, and never on the same page. The studies live in different countries, different decades and different patient groups, and their numbers are usually quoted one at a time, stripped of the population that produced them. This page joins them into one chain, with the study, the population and the year attached to every link, and the sting-specific figures separated from the food-allergy figures wherever the research allows it. The headline finding is not that the device fails. It is that the chain usually breaks at a decision, not at the device: in the best-measured cohort, patients who physically had an auto-injector with them during anaphylaxis used it before hospital only 41% of the time (Gabrielli et al., C-CARE subset analysis, as reported in J Mark Access Health Policy (2026), 2017).

The safety guidance comes before the analysis, because it is short and it does not depend on any statistic. Trouble breathing, throat tightness, widespread hives, dizziness or collapse after a sting is anaphylaxis: guidelines say to use epinephrine at the first sign of a systemic reaction rather than waiting to see how it develops, to carry two devices because one may not be enough, and to get emergency care after any use — StingHelp’s guides to the warning signs of a systemic sting reaction and to venom allergy and multiple stings cover the recognition side in detail. Everything below is about what the recorded data say happens in practice, reported without blame: the studies consistently describe training and system gaps, not careless patients.

1 How Many People Actually Carry It at All Times?

In most measured populations, a minority. The only sting-specific carriage study found that fewer than 30% of venom-allergy patients carried their EpiPen at all times (Goldberg & Confino-Cohen (J Allergy Clin Immunol, 2000), 2000); a large US survey of people who had filled at least one prescription put always-carrying at 50% (Portnoy et al., RACE survey (JACI: In Practice, 2019), as reported in J Mark Access Health Policy (2026), 2014); and at the extremes sit Dutch teenagers, at 20%, and one intensively counselled German venom cohort, at 69.9%. The spread is not noise — it tracks how much follow-up and training each population actually received.

METRICVALUESOURCE
Venom-allergy patients carrying their EpiPen at all times (Israel)30%Goldberg & Confino-Cohen (J Allergy Clin Immunol, 2000)
Venom-allergy patients who declined immunotherapy and routinely carried a device (Germany)69.9%Ueberschaar et al. (Allergy Asthma Clin Immunol, 2026)
US patients who carried at all times during the previous week (RACE survey)50%Portnoy et al., RACE survey (JACI: In Practice, 2019), as reported in J Mark Access Health Policy (2026)
Canadians at risk who did not consistently carry their device57%Canadian survey, as reported in J Mark Access Health Policy (2026)
Italian allergy-clinic patients who did not always carry their device18%Ridolo et al. (Intern Emerg Med, 2015)
Dutch teenagers with serious food allergy who had a device with them at all times20%Saleh-Langenberg & Dubois, University Medical Center Groningen (2016)
69.9%
The German cohort is the exception that identifies the lever: every patient left with a kit, a printed action plan and refresher training at follow-up — and reported the highest carriage in this dataset.
Ueberschaar et al. (Allergy Asthma Clin Immunol, 2026), 2021

The two venom studies bracket the whole table, and the distance between them is the story. In the Israeli clinic study, carrying was worst among patients furthest along in immunotherapy — the safer they became, the less they carried. In the German cohort, patients who had declined that same therapy carried at 69.9%, after a centre that handed over the kit, the action plan and the training together and kept refreshing them. Carriage, in other words, behaves less like a personality trait and more like a maintenance task: it decays unless something renews it. The everyday frictions are real — devices are bulky, two are recommended, and replacements come round quickly, which is why StingHelp’s page on whether an expired EpiPen can still be used and its comparison of EpiPen and Auvi-Q both end up being read as carriage pages, not product pages.

2 Was the Device There When the Reaction Hit?

Usually, yes — where a prescription exists at all. In the UK episode survey, self-injectable adrenaline was available at the scene in 79% of episodes (Sheikh et al. (JRSM Open, 2015), 2013), and children had it available even more often than adults. The Japanese data show the chain breaking one link earlier: of the survivors surveyed, 95 of 678 had been prescribed a device at the time of their episode, and 74.2% had no prescription at all (Nakamura et al. (Asia Pacific Allergy, 2025), 2020). Presence is the strongest link in the chain; getting the prescription written is, in some systems, the weakest.

METRICVALUESOURCE
Episodes where adrenaline was available at the scene (UK, all ages)79%Sheikh et al. (JRSM Open, 2015)
Episodes in children where adrenaline was available (UK)82%Sheikh et al. (JRSM Open, 2015)
Episodes in adults where adrenaline was available (UK)74%Sheikh et al. (JRSM Open, 2015)
Japanese survivors prescribed a device at the time of the episode95 of 678Nakamura et al. (Asia Pacific Allergy, 2025)
Japanese survivors with no prescription at the time of the episode74.2%Nakamura et al. (Asia Pacific Allergy, 2025)
Non-use episodes blamed on the device not being available (UK paediatric full text)5%Noimark et al. (Clin Exp Allergy, 2012), full-text figure via NHS clinician summary
5%
When UK families explained why adrenaline was not used, the device not being there was cited in only a small minority of episodes — the explanations were overwhelmingly judgement calls, listed in the final section.
Noimark et al. (Clin Exp Allergy, 2012), full-text figure via NHS clinician summary, 2011

Two cautions belong on this section’s numbers. The UK figures come from members of a patient charity — people engaged enough to join the Anaphylaxis Campaign and complete its questionnaire — so availability in the wider population is plausibly lower, not higher. And availability is measured per episode, not per person: a device in a school office or a kitchen drawer counts as available, which is exactly the definition that matters in the moment and exactly the one that flatters the statistic. Even with both cautions, the ordering of the links is consistent across every dataset on this page: presence outperforms use, by a wide margin, everywhere it has been measured.

3 How Often Is It Used Before Hospital Care?

A minority of the time, in every registry and cohort that has counted. Across the full Canadian registry cohort, epinephrine was given before hospital in 31% of cases (Gabrielli et al. (JACI: In Practice, 2019), 2017); among patients who had a device accessible during the reaction, use rose only to 41%. Antihistamines were given more often than epinephrine in the same cohort, at 46% (Gabrielli et al. (JACI: In Practice, 2019), 2017). The most recent children’s cohort, from Montreal, records the highest rate in the table — and it is still below half, at 44%.

METRICVALUESOURCE
Patients with an auto-injector accessible during the reaction who used it before hospital arrival (C-CARE subset, Canada)41%Gabrielli et al., C-CARE subset analysis, as reported in J Mark Access Health Policy (2026)
All registry cases given epinephrine before hospital (Canada, full cohort)31%Gabrielli et al. (JACI: In Practice, 2019)
Registry reactions given prehospital epinephrine, 2011-2022 data (Canada)37.9%Delli Colli et al. (Ann Allergy Asthma Immunol, 2023)
Episodes where available adrenaline was used (UK)38%Sheikh et al. (JRSM Open, 2015)
Children receiving epinephrine before ED arrival (US)36.3%Robinson et al. (Ann Allergy Asthma Immunol, 2017)
Children receiving epinephrine before hospital (Montreal, to 2023)44%Khalaf et al. (JACI: In Practice, 2025), via McGill University Health Centre
UK children and teenagers who used their device during anaphylaxis16.7%Noimark et al. (Clin Exp Allergy, 2012)
Japanese survivors who used a device at their most recent episode7.2%Nakamura et al. (Asia Pacific Allergy, 2025)
Japanese survivors with bee-venom anaphylaxis who used a device18.2%Nakamura et al. (Asia Pacific Allergy, 2025)
5.2%
Japan’s survey counted the carried-but-not-used directly: the group that had the device in hand and did not use it was nearly as large as the group that used it.
Nakamura et al. (Asia Pacific Allergy, 2025), 2020

Epinephrine given before hospital arrival, percent of anaphylaxis cases

All anaphylaxis cases receiving epinephrine before hospital

31%
Anaphylaxis reactions receiving epinephrine in the prehospit

37.9%
Children with anaphylaxis who received epinephrine before ED

36.3%
Children with anaphylaxis who received epinephrine before ho

44%

The pattern inside the rates matters as much as the rates. Children used available adrenaline less often than adults — 30% against 54% in the UK episodes — despite having it available more often, because the decision is usually made by a watching adult under stress. The historical floor is the survivor survey, where 27% of survivors used a device during their most severe episode (Simons, Clark & Camargo (J Allergy Clin Immunol, 2009), 2009), and the studies since describe slow improvement rather than a solved problem. Japan’s chain is the most completely counted: of the survivors who had been prescribed a device, 49 of 95 used it, while the carried-but-not-used group shows the hesitation in its purest form — no access problem, no prescription problem, a device in hand and a decision not taken.

The outcome data explain why this link carries the argument of the whole page. In the Montreal cohort, children who received epinephrine before hospital were admitted to intensive care at 0.7%, against 1.6% for those who did not (Khalaf et al. (JACI: In Practice, 2025), via McGill University Health Centre, 2023); in the Canadian registry, prehospital treatment cut the odds of needing multiple doses in the emergency department sharply ((Gabrielli et al. (JACI: In Practice, 2019), 2017)). These are observational associations, not trial results — no trial will ever randomise withholding epinephrine — but they are the reason guidelines are written the way they are, and why StingHelp’s guidance on when to give a second dose and what to do after using an EpiPen starts from use first, hospital immediately after.

4 Can Patients Use It Correctly?

In observed trainer tests, a minority manage every step. Among venom-allergy patients, 44% demonstrated proper EpiPen technique (Goldberg & Confino-Cohen (J Allergy Clin Immunol, 2000), 2000); among Italian allergy-clinic patients who had held a prescription for at least a year, 39% managed the device properly (Ridolo et al. (Intern Emerg Med, 2015), 2013). Complete failure was rare — most people did most of it right and missed a step that mattered.

METRICVALUESOURCE
Venom-allergy patients demonstrating proper technique (Israel)44%Goldberg & Confino-Cohen (J Allergy Clin Immunol, 2000)
Italian clinic patients managing the device properly in a four-step test39%Ridolo et al. (Intern Emerg Med, 2015)
Italian patients who failed all four steps of the test6%Ridolo et al. (Intern Emerg Med, 2015)
Previously prescribed patients unable to demonstrate accurate technique (Bonds et al.)84%Bonds et al., as reported in J Asthma Allergy (2018) review
6%
Total failure was uncommon; the typical result was a near-miss — most steps right, one step wrong — which is precisely the failure mode refresher practice exists to catch.
Ridolo et al. (Intern Emerg Med, 2015), 2013

Patients demonstrating correct auto-injector technique, percent

Venom-allergy patients who demonstrated proper EpiPen admini

44%
Italian allergy-clinic patients who properly managed the dev

39%

The widest figure in this table, the 84% unable to demonstrate accurate technique reported for the Bonds cohort, used the strictest standard of the three studies, and it is carried here as a secondary figure via a review for exactly that reason: the three numbers are not measuring identical tests, and presenting them as one scale would repeat the sin this page exists to correct. What the studies agree on is the lever. In the Israeli study, technique tracked who had done the teaching — instruction from an allergist, not from anyone else, predicted a correct demonstration. In the Italian study, patient education was again the factor most closely related to proper use, while time since first prescription made no difference: skill does not fade on a schedule, it fades without rehearsal. It is in this context that regulators are now looking at needle-free adrenaline: in October 2026 the UK medicines regulator opened a consultation on letting schools stock spare adrenaline nasal sprays alongside auto-injectors, a policy discussion that exists because the injection step is where the chain keeps breaking. (That consultation is context for this page, not one of its statistics.)

5 Why People Don't Use It: The Recorded Reasons

The recorded reasons are dominated by one judgement: that the reaction did not warrant it. In the UK paediatric study, 54.4% of non-use was explained as ‘thought adrenaline unnecessary’ (Noimark et al. (Clin Exp Allergy, 2012), 2011) and a further 19.1% as ‘unsure adrenaline necessary’. In the survivor survey, the commonest behaviour was substitution — 38% of non-users took an antihistamine instead (Simons, Clark & Camargo (J Allergy Clin Immunol, 2009), 2009). Fear, absence and cost all appear in the literature; none of them leads it.

METRICVALUESOURCE
‘Thought adrenaline unnecessary’ (UK paediatric study)54.4%Noimark et al. (Clin Exp Allergy, 2012)
‘Unsure adrenaline necessary’ (UK paediatric study)19.1%Noimark et al. (Clin Exp Allergy, 2012)
Took an antihistamine instead (survivor survey)38%Simons, Clark & Camargo (J Allergy Clin Immunol, 2009)
Had no prescription (survivor survey)28%Simons, Clark & Camargo (J Allergy Clin Immunol, 2009)
Judged the episode mild (survivor survey)13%Simons, Clark & Camargo (J Allergy Clin Immunol, 2009)
Venom patients who planned to wait for more symptoms after a re-sting54%Goldberg & Confino-Cohen (J Allergy Clin Immunol, 2000)
Venom patients who planned to inject immediately after a re-sting22%Goldberg & Confino-Cohen (J Allergy Clin Immunol, 2000)
Italian patients who had faced real doubt about whether to use adrenaline14%Ridolo et al. (Intern Emerg Med, 2015)
54%
The hesitation is not only a panic response: measured calmly in a clinic, most venom-allergy patients said in advance that after a re-sting they would wait for more symptoms before acting.
Goldberg & Confino-Cohen (J Allergy Clin Immunol, 2000), 2000

Read together, the reasons describe a recognition problem, not a defiance problem. Anaphylaxis often begins with symptoms that look mild, and the survivor survey contains its own corrective: non-users’ episodes involved multiple organ systems at nearly the same rate as users’ episodes, so ‘mild’ was frequently a description applied in the moment to an event that was not mild by the study’s own record. The sting-specific version of the same moment is the hardest one in this dataset to read past: only 22% of venom-allergy patients said they would inject immediately after a re-sting, in a group whose risk is known, diagnosed and carried in their pocket. Distinguishing a big local reaction from a systemic one is part of that moment, and StingHelp’s large local reaction versus anaphylaxis comparison exists for it — but the guideline answer to the doubt itself is deliberately simple, because doubt is the measured default: treat the first systemic signs, then get emergency care.

Nothing in this data supports reading non-use as carelessness. The same studies record devices prescribed without training, training given once and never refreshed, and action plans absent in most households — the survivor survey found most participants, users and non-users alike, had no written plan at all. A written plan is the decision made in advance, in a calm room, instead of at the worst moment; StingHelp’s sting allergy action plan checklist is built to be exactly that. The chain on this page breaks at predictable links, and every one of them — the prescription, the carriage habit, the rehearsed decision, the practised hand — is a link that preparation reaches before the sting does.

Key statistics: Epinephrine Auto-Injector Carry and Use Rates: Carried, Present, Used, Used Right (2026)
Key statistics at a glance | Source: see numbered sources below

Explore every figure in this article

MetricValueYearSource
Venom-allergy patients who carried their EpiPen at all times (reported as 'less than 30%')30%2000Goldberg & Confino-Cohen (J Allergy Clin Immunol, 2000)
Venom-allergy patients who declined immunotherapy and reported routinely carrying an epinephrine auto-injector (Germany)69.9%2021Ueberschaar et al. (Allergy Asthma Clin Immunol, 2026)
US patients who carried their auto-injector at all times during the previous week (RACE survey, n=2,000)50%2014Portnoy et al., RACE survey (JACI: In Practice, 2019), as reported in J Mark Access Health Policy (2026)
People at risk of anaphylaxis in Canada who did not consistently carry their auto-injector57%2026Canadian survey, as reported in J Mark Access Health Policy (2026)
Italian allergy-clinic patients who did not always carry their auto-injector18%2013Ridolo et al. (Intern Emerg Med, 2015)
Dutch teenagers (11-20) with a serious food allergy who had an EpiPen with them at all times20%2016Saleh-Langenberg & Dubois, University Medical Center Groningen (2016)
Anaphylaxis episodes in which self-injectable adrenaline was available at the scene (UK)79%2013Sheikh et al. (JRSM Open, 2015)
Episodes in children in which adrenaline was available at the scene (UK)82%2013Sheikh et al. (JRSM Open, 2015)
Episodes in adults in which adrenaline was available at the scene (UK)74%2013Sheikh et al. (JRSM Open, 2015)
Japanese anaphylaxis survivors who had been prescribed an auto-injector at the time of their most recent episode95 of 6782020Nakamura et al. (Asia Pacific Allergy, 2025)
Japanese survivors who had no auto-injector prescription at the time of the episode74.2%2020Nakamura et al. (Asia Pacific Allergy, 2025)
Non-use episodes in which the device simply not being available was the reason given (UK paediatric study, full text)5%2011Noimark et al. (Clin Exp Allergy, 2012), full-text figure via NHS clinician summary
Patients with an auto-injector accessible during the reaction who used it before hospital arrival (C-CARE subset, Canada)41%2017Gabrielli et al., C-CARE subset analysis, as reported in J Mark Access Health Policy (2026)
All anaphylaxis cases receiving epinephrine before hospital arrival (C-CARE, 3,498 cases)31%2017Gabrielli et al. (JACI: In Practice, 2019)
Anaphylaxis reactions receiving epinephrine in the prehospital setting (C-CARE, 5,364 reactions, 2011-2022)37.9%2022Delli Colli et al. (Ann Allergy Asthma Immunol, 2023)
Episodes in which available adrenaline was actually used (UK)38%2013Sheikh et al. (JRSM Open, 2015)
Episodes in children in which available adrenaline was used (UK)30%2013Sheikh et al. (JRSM Open, 2015)
Episodes in adults in which available adrenaline was used (UK)54%2013Sheikh et al. (JRSM Open, 2015)
Children with anaphylaxis who received epinephrine before ED or urgent-care arrival (US, 408 patients)36.3%2013Robinson et al. (Ann Allergy Asthma Immunol, 2017)
Children with anaphylaxis who received epinephrine before hospital arrival (Montreal, 3,158 patients, 2011-2023)44%2023Khalaf et al. (JACI: In Practice, 2025), via McGill University Health Centre
Anaphylaxis survivors who used an auto-injector for first-aid treatment of their most severe episode (2009 survey)27%2009Simons, Clark & Camargo (J Allergy Clin Immunol, 2009)
UK children and teenagers who used their auto-injector during anaphylaxis16.7%2011Noimark et al. (Clin Exp Allergy, 2012)
Japanese survivors who used an auto-injector at their most recent episode (all respondents)7.2%2020Nakamura et al. (Asia Pacific Allergy, 2025)
Japanese survivors whose episode was caused by bee venom and who used an auto-injector18.2%2020Nakamura et al. (Asia Pacific Allergy, 2025)
Japanese survivors who carried their auto-injector at the episode but did not use it5.2%2020Nakamura et al. (Asia Pacific Allergy, 2025)
Japanese survivors with a prescription who used the device at the episode49 of 952020Nakamura et al. (Asia Pacific Allergy, 2025)
Anaphylaxis cases given antihistamines before hospital arrival (C-CARE)46%2017Gabrielli et al. (JACI: In Practice, 2019)
ICU admission rate in children who did not receive epinephrine before hospital (Montreal)1.6%2023Khalaf et al. (JACI: In Practice, 2025), via McGill University Health Centre
ICU admission rate in children who received epinephrine before hospital (Montreal)0.7%2023Khalaf et al. (JACI: In Practice, 2025), via McGill University Health Centre
Adjusted odds ratio for needing multiple epinephrine doses in the ED after prehospital epinephrine (C-CARE)0.232017Gabrielli et al. (JACI: In Practice, 2019)
Venom-allergy patients who demonstrated proper EpiPen administration technique on a trainer44%2000Goldberg & Confino-Cohen (J Allergy Clin Immunol, 2000)
Italian allergy-clinic patients who properly managed the device in a four-step trainer test39%2013Ridolo et al. (Intern Emerg Med, 2015)
Italian patients who failed all four steps of the trainer test6%2013Ridolo et al. (Intern Emerg Med, 2015)
Patients with previous auto-injector prescriptions who could not demonstrate accurate technique (Bonds et al.)84%2018Bonds et al., as reported in J Asthma Allergy (2018) review
Reason given for not using adrenaline: 'thought adrenaline unnecessary' (UK paediatric study)54.4%2011Noimark et al. (Clin Exp Allergy, 2012)
Reason given: 'unsure adrenaline necessary' (UK paediatric study)19.1%2011Noimark et al. (Clin Exp Allergy, 2012)
Non-users who took or gave an H1-antihistamine instead (survivor survey)38%2009Simons, Clark & Camargo (J Allergy Clin Immunol, 2009)
Non-users who had no prescription for epinephrine (survivor survey)28%2009Simons, Clark & Camargo (J Allergy Clin Immunol, 2009)
Non-users who judged the episode mild (survivor survey)13%2009Simons, Clark & Camargo (J Allergy Clin Immunol, 2009)
Venom-allergy patients who said that after a re-sting they would wait for other symptoms before acting54%2000Goldberg & Confino-Cohen (J Allergy Clin Immunol, 2000)
Venom-allergy patients who said they would administer their EpiPen immediately after a re-sting22%2000Goldberg & Confino-Cohen (J Allergy Clin Immunol, 2000)
Italian patients who reported past situations in which they had been doubtful about whether to use adrenaline14%2013Ridolo et al. (Intern Emerg Med, 2015)
Comparison chart: Epinephrine Auto-Injector Carry and Use Rates: Carried, Present, Used, Used Right (2026)
Comparison | Source: see numbered sources below

Methodology

This page was built by the Data Gap Method in a degraded run, and the degraded stages are part of the record. Stage one demand for this topic was unmeasured: no usable thread counts exist for it in this run (the Reddit route is blocked from this host, and demand mining ran manually through host web search), so the topic was carried on the strength of the studies themselves rather than a demand score. Stage two ran on web search rather than a SERP API. The stage three format filter did not run. Stage four’s existence gate was applied manually against the site’s 689-URL sitemap corpus, which is also the only source of this page’s internal links. Stage six recency ran as a fallback: the sweep script crashed on its Reddit leg (an incomplete-read error, the same host failure as the previous runs), so host web searches were used instead; they found no new study inside the thirty-day window that revises any rate used here — the freshest in-window items are a UK regulator consultation on school stocks of adrenaline nasal spray and a Canadian conference poster on hesitation barriers, both context, neither a number. On verification: the scripted checker verified 24 of the 56 fact entries against their source pages. The remaining 32 sit on hosts the checker could not read from this machine — PubMed returned an error status to the script, one university page failed to load for it, and one publisher served it a JavaScript shell — and every one of those values was read verbatim from the source through a browser before being used, the same remedy applied in the previous run. Two figures are secondary by construction and are labelled so where they appear: the 41% device-in-hand rate (the registry’s subset analysis, reported in a 2026 journal paper and corroborated verbatim by the authors’ own institution release — that release was read in full here, but its host refuses scripted connections from this machine, so the journal paper carries the citation) and the Bonds technique figure (reported in a 2018 review). One honest limitation governs the whole page: no two rates here share a population or a denominator, so they are presented as a chain of labelled links and are never averaged or multiplied into a single success rate; the sting-specific behavioural figures are also the oldest in the set, from 2000, because no later study has re-measured carriage and technique in venom-allergy patients. No paid API, tool or data source was used at any stage.

  • Sources consulted: 41
  • Sources cited: 15
  • Data freshness: current year: 2, last year: 2, older: 11
  • Data range: 2000-01-01 to 2026-11-13
  • Research date: 2026-11-13
  • Update schedule: Annual
  • Limitations: Every rate in this dataset comes from a different population and denominator — clinic patients, charity members, survey respondents, ED arrivals, registry cases — so the figures are presented as a chain of separately labelled links, never averaged and never multiplied into a single success rate. The sting-specific behavioural data are the oldest in the set (2000) because no newer study has re-measured carriage and technique in venom-allergy patients; that gap is stated wherever those figures are used. Two figures are secondary: the 41% device-in-hand rate (the registry's subset analysis, reported in a 2026 journal paper and corroborated verbatim by the authors' institution release, which was read in full in a browser but refuses scripted connections from this machine) and the Bonds et al. technique figure (via a 2018 review).

Frequently Asked Questions

If an auto-injector is right there during anaphylaxis, how often is it actually used?

Less than half the time in the studies that measured it directly. In 483 Canadian cases of food-induced anaphylaxis where patients had a device with them, 41% used it before hospital (Gabrielli et al., 2019); in a UK episode survey, adrenaline was available in 79% of episodes and used in 38% (Sheikh et al., 2015). Presence and use are two different numbers everywhere they have been measured. (Gabrielli et al., C-CARE subset analysis (2019); Sheikh et al. (2015), 2017)

Do most people carry their EpiPen at all times?

No study in this dataset found a carrying majority among general patient populations. Fewer than 30% of venom-allergy patients carried their EpiPen at all times (Goldberg & Confino-Cohen, 2000); in the US RACE survey of 2,000 people who had filled a prescription, 50% had carried it at all times during the previous week. One heavily counselled German cohort reported 69.9% routine carriage — the exception that shows what sustained follow-up can do. (Goldberg & Confino-Cohen (2000); Portnoy et al. (2019), 2000)

What is the most common reason people give for not using their auto-injector?

Judging the moment wrong. In the 14-clinic UK paediatric study, 54.4% of non-use was explained as 'thought adrenaline unnecessary' and a further 19.1% as 'unsure adrenaline necessary' (Noimark et al., 2012). In the 2009 survivor survey, 38% of non-users had taken an antihistamine instead (Simons et al., 2009). The device not being there was cited in only about 5% of episodes in the UK study's full text. (Noimark et al. (2012); Simons et al. (2009), 2011)

Can most patients use an auto-injector correctly?

In observed trainer tests, no. Among venom-allergy patients, 44% demonstrated proper EpiPen technique (Goldberg & Confino-Cohen, 2000); among Italian allergy-clinic patients prescribed a device for at least a year, 39% managed it properly and 6% failed every step (Ridolo et al., 2015). Both studies found the same lever: instruction from an allergist, repeated, is what moves the number. (Goldberg & Confino-Cohen (2000); Ridolo et al. (2015), 2013)

Does using epinephrine before hospital actually change outcomes?

The registry and cohort data say yes. In a propensity-matched Montreal cohort of 3,158 children, ICU admission was 1.6% without prehospital epinephrine and 0.7% with it (Khalaf et al., 2025). In the Canadian C-CARE cohort, patients treated before arrival were far less likely to need multiple epinephrine doses in the ED (adjusted OR 0.23; Gabrielli et al., 2019). These are associations from observational data, not randomised trials — none exist for withholding epinephrine. (Khalaf et al. (2025); Gabrielli et al. (2019), 2023)

I have a sting allergy — what do the numbers say about people like me?

The sting-specific data are the oldest and the starkest. Among venom-allergy patients in the Israeli clinic study, fewer than 30% carried their EpiPen at all times, 54% planned to wait for more symptoms after a re-sting, and 44% could demonstrate correct technique (Goldberg & Confino-Cohen, 2000). In Japan's 2025 survey, bee venom was the trigger group most likely to use a device — 18.2% did (Nakamura et al., 2025). Guidelines written since these studies answer them directly: carry two devices, use epinephrine at the first sign of a systemic reaction, and get emergency care afterwards. (Goldberg & Confino-Cohen (2000); Nakamura et al. (2025), 2000)

Have carry and use rates improved over time?

Slowly, and only into a higher minority. Survivor-survey use was 27% in 2009 (Simons et al.); Canadian registry prehospital epinephrine was 31% of cases in 2019 and 37.9% across the registry's 2011-2022 data (Gabrielli et al., 2019; Delli Colli et al., 2023); the Montreal children's cohort reached 44% in data running to 2023 (Khalaf et al., 2025). Sixteen years of guidelines, training and device redesign have not yet produced a majority anywhere. (Delli Colli et al. (2023), 2022)

Sources & References

  1. Goldberg & Confino-Cohen. “Insect sting-inflicted systemic reactions: attitudes of patients with insect venom allergy regarding after-sting behavior and proper administration of epinephrine.” pubmed.ncbi.nlm.nih.gov/11112904/. Accessed 2026-11-13.
  2. Ueberschaar, Trautmann & Stoevesandt. “Declining venom immunotherapy: patient characteristics and clinical outcomes.” link.springer.com/article/10.1186/s13223-026-01046-w. Accessed 2026-11-13.
  3. J Mark Access Health Policy (2026). “Real-World Shelf Life of Epinephrine Auto-Injectors in Canada: Implications for Renewal Frequency and Patient Burden.” mdpi.com/2001-6689/14/3/54. Accessed 2026-11-13.
  4. Ridolo et al.. “How far from correct is the use of adrenaline auto-injectors? A survey in Italian patients.” pubmed.ncbi.nlm.nih.gov/25990486/. Accessed 2026-11-13.
  5. University Medical Center Groningen. “Eighty percent of teenagers with a food allergy do not carry a life-saving injector.” rug.nl/news/2016/08/eighty-percent-of-teenagers-with-a-food-allergy-do-not-carry. Accessed 2026-11-13.
  6. Nakamura et al.. “Internet survey on EpiPen adrenaline autoinjector usage in Japanese patients with a history of anaphylaxis.” pmc.ncbi.nlm.nih.gov/articles/PMC12672169/. Accessed 2026-11-13.
  7. Sheikh et al.. “Anaphylaxis in the community: a questionnaire survey of members of the UK Anaphylaxis Campaign.” pmc.ncbi.nlm.nih.gov/articles/PMC5167076/. Accessed 2026-11-13.
  8. Gabrielli et al.. “Evaluation of Prehospital Management in a Canadian Emergency Department Anaphylaxis Cohort.” pubmed.ncbi.nlm.nih.gov/31035000/. Accessed 2026-11-13.
  9. Delli Colli et al.. “Managing anaphylaxis: epinephrine, antihistamines, and corticosteroids — more than 10 years of Cross-Canada Anaphylaxis REgistry data.” reference.medscape.com/medline/abstract/37689113. Accessed 2026-11-13.
  10. Robinson et al.. “Factors associated with epinephrine administration for anaphylaxis in children before arrival to the emergency department.” pubmed.ncbi.nlm.nih.gov/28711194/. Accessed 2026-11-13.
  11. McGill University Health Centre. “Epinephrine could reduce hospitalizations in pediatric intensive care after a severe allergic reaction.” muhc.ca/news-and-patient-stories/epinephrine-could-reduce-hospitalizations-pedia. Accessed 2026-11-13.
  12. Noimark et al.. “The use of adrenaline autoinjectors by children and teenagers.” pubmed.ncbi.nlm.nih.gov/22181034/. Accessed 2026-11-13.
  13. Simons, Clark & Camargo. “Anaphylaxis in the community: learning from the survivors.” pubmed.ncbi.nlm.nih.gov/19540575/. Accessed 2026-11-13.
  14. J Asthma Allergy (2018). “Underuse of epinephrine for the treatment of anaphylaxis: missed opportunities.” pmc.ncbi.nlm.nih.gov/articles/PMC6016581/. Accessed 2026-11-13.
  15. Scottish Paediatric Epilepsy Network education pages. “Adrenaline autoinjectors (summary of Noimark et al. full text).” scottishpaeds.org.uk/2015/03/30/adrenaline-autoinjectors/. Accessed 2026-11-13.

Last updated:


This article is for informational purposes only and isn’t medical advice. If you’re worried about a bite or sting, talk to a healthcare professional.

SJ

Dr. Sarah Jones, MD

MD — Medical Reviewer · Board-Certified Emergency Medicine Physician

Dr. Jones oversees StingHelp’s clinical verification process. Every guide is systematically evaluated against active Centers for Disease Control and Prevention (CDC), Environmental Protection Agency (EPA), and American Academy of Allergy, Asthma & Immunology (AAAAI) medical consensus standards to ensure symptom distinctions and care recommendations are clinically sound.

How this guide was prepared: Researched and structured by the StingHelp Editorial Team; verified against peer-reviewed dermatology literature; clinically reviewed November 2026.